Results 251 to 260 of about 54,917 (299)
eGFR- and Potassium-Guided Stewardship of SGLT2 Inhibitors and Finerenone in Albuminuric Chronic Kidney Disease Associated with Type 2 Diabetes. [PDF]
Diabetes Metab Syndr ObesSu C, Li X, Wang S, Liu D.
europepmc +1 more source
From cancer safety signals to cardio-oncology translation: a dual-database bibliometric and BERTopic semantic analysis of SGLT2 inhibitor research in oncology (2014-2026). [PDF]
Front OncolTang X, Niu W, Lan Z, Zhong Z.
europepmc +1 more source
Study Protocol for the TIGHTEN Study Comparing the Effects of Tofogliflozin and Glimepiride on Skeletal Muscle Mass in Patients with Type 2 Diabetes without Obesity: A Prospective, Multicenter, Open-Label, Randomized, Parallel Group Trial in Japan. [PDF]
Diabetes TherTakeda Y +7 more
europepmc +1 more source
Assessing clinical relevance of off-target effects observed at suprapharmacological concentrations of SGLT2 inhibitors. [PDF]
J Clin InvestTaylor SI.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Biochemical Pharmacology, 2016
Diabetes mellitus is a serious health issue and an economic burden, rising in epidemic proportions over the last few decades worldwide. Although several treatment options are available, only half of the global diabetic population achieves the recommended or individualized glycemic targets.
I, Dardi, T, Kouvatsos, S A, Jabbour
openaire +2 more sources
Diabetes mellitus is a serious health issue and an economic burden, rising in epidemic proportions over the last few decades worldwide. Although several treatment options are available, only half of the global diabetic population achieves the recommended or individualized glycemic targets.
I, Dardi, T, Kouvatsos, S A, Jabbour
openaire +2 more sources
Abstract SGLT2 inhibitors were first introduced for heart failure in 2020 and are now first-line agents for all patients with symptomatic heart failure regardless of left ventricular ejection fraction. They reduce both morbidity and mortality in clinical trials with an average relative risk reduction of 23% for heart failure ...
Roy S. Gardner +3 more
openaire +2 more sources
Roy S. Gardner +3 more
openaire +2 more sources
Current Opinion in Cardiology, 2018
To address common concerns regarding sodium-glucose cotransporter 2 (SGLT2) inhibitor use for patients with type 2 diabetes mellitus (T2DM) in cardiovascular practice.SGLT2 inhibitors provide glycemic control and improve cardiovascular and renal endpoints in T2DM.
Erika, Opingari +3 more
openaire +2 more sources
To address common concerns regarding sodium-glucose cotransporter 2 (SGLT2) inhibitor use for patients with type 2 diabetes mellitus (T2DM) in cardiovascular practice.SGLT2 inhibitors provide glycemic control and improve cardiovascular and renal endpoints in T2DM.
Erika, Opingari +3 more
openaire +2 more sources